Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/19 12:10:48 am
0.45 AUD   -1.10%
2021Immutep Taps Northway Biotech To Manufature Autoimmune Drug IMP761
MT
2021IMMUTEP : Advances IMP761 Manufacturing - Form 6-K
PU
2021Immutep Limited Advances IMP761 Manufacturing
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : Results of Annual General Meeting

11/25/2021 | 09:10pm EST

ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA - 26 November 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2.

Please be advised that all resolutions in the Company's 2021 Notice of Annual General Meeting were passed by the requisite majorities at today's AGM.

All resolutions were passed and decided by way of poll.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

Further information can be found on the Company's website www.immutep.comor by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Immutep Limited

Annual General Meeting

Friday, 26 November 2021

Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details

Resolution

Resolution

Type

1.

Adoption of Remuneration

Ordinary

Report

2.

Re-election of Director - Dr

Ordinary

Russell Howard

3.

Ratification of previous Share

Ordinary

issue

4.

Approval of grant of

performance rights to Dr Russell

Ordinary

Howard

5.

Approval of the use of

performance rights and/or options

Ordinary

under the Company's Executive

Incentive Plan

6.

Approval of grant of

performance rights to Mr Marc

Ordinary

Voigt

7.

Approval of Amendment to

Special

Constitution

8.

Approval of Proportional

Special

Takeover Provisions

Instructions given to validly appointed proxies

Direct votes

Number of votes cast on the poll

(as at proxy close)

(as at close of direct voting)

(where applicable)

For

Against

Proxy's

Abstain

For

Against

Abstain

For

Against

Abstain*

Discretion

274,582,622

1,160,762

1,803,064

843,134

9,845,075

127,337

30,024

286,579,383

1,290,099

873,158

99.55%

0.45%

279,327,851

1,459,484

1,905,023

899,642

20,861,709

3,235

7,443

302,445,205

1,462,719

907,085

99.52%

0.48%

218,401,812

2,041,473

1,659,093

57,037,067

20,373,847

310,667

187,873

240,785,374

2,352,140

57,224,940

99.03%

0.97%

272,208,059

7,149,516

1,855,950

1,628,475

20,026,155

818,873

27,359

294,563,786

7,770,389

1,730,834

97.43%

2.57%

273,775,534

7,596,947

1,865,950

353,569

9,545,972

582,987

2,989,664

285,461,078

8,181,934

3,418,233

97.21%

2.79%

220,099,588

60,109,222

1,583,939

1,799,251

20,036,491

808,537

27,359

242,193,640

60,719,759

1,901,610

79.95%

20.05%

273,727,014

7,591,483

1,521,081

752,422

20,459,980

333,623

78,784

296,058,697

7,925,106

831,206

97.39%

2.61%

279,890,215

1,522,645

1,521,081

658,059

20,505,118

278,855

88,414

302,267,036

1,801,500

746,473

99.41%

0.59%

Resolution

If s250U

Result

applies

Carried /

Not Carried

Carried

No

CarriedNA

CarriedNA

CarriedNA

CarriedNA

CarriedNA

CarriedNA

CarriedNA

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Disclaimer

Immutep Ltd. published this content on 26 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2021 02:09:02 UTC.


© Publicnow 2021
All news about IMMUTEP LIMITED
2021Immutep Taps Northway Biotech To Manufature Autoimmune Drug IMP761
MT
2021IMMUTEP : Advances IMP761 Manufacturing - Form 6-K
PU
2021Immutep Limited Advances IMP761 Manufacturing
CI
2021Immutep Signs Deal for Clinical Trial Production of Autoimmune Drug
MT
2021IMMUTEP : Advances IMP761 Manufacturing
PU
2021IMMUTEP : Amended Constitution
PU
2021Immutep Limited Announces Change of Registered Office Address, Effective 15 December 20..
CI
2021IMMUTEP : Change in substantial holding
PU
2021IMMUTEP : REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI ..
PU
2021Immutep Doses First Five Patients in Study of Triple Combination Cancer Treatment, Find..
MT
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 3,50 M 2,52 M 2,52 M
Net income 2022 -38,6 M -27,7 M -27,7 M
Net cash 2022 78,5 M 56,4 M 56,4 M
P/E ratio 2022 -7,07x
Yield 2022 -
Capitalization 389 M 279 M 279 M
EV / Sales 2022 88,6x
EV / Sales 2023 119x
Nbr of Employees -
Free-Float -
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,46 AUD
Average target price 1,17 AUD
Spread / Average Target 157%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
Frédéric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED-7.14%279
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707